NO20063436L - Intranasal administrasjon av glukose-regulerende peptider - Google Patents
Intranasal administrasjon av glukose-regulerende peptiderInfo
- Publication number
- NO20063436L NO20063436L NO20063436A NO20063436A NO20063436L NO 20063436 L NO20063436 L NO 20063436L NO 20063436 A NO20063436 A NO 20063436A NO 20063436 A NO20063436 A NO 20063436A NO 20063436 L NO20063436 L NO 20063436L
- Authority
- NO
- Norway
- Prior art keywords
- intranasal administration
- regulatory peptides
- glucose regulatory
- glucose
- amylin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Det er beskrevet farmasøytiske sammensetninger og fremgangsmåter omfattende minst et glukose-regulerende peptid, slik som amylin, glucagon-liknende peptid-1 (GLP), pramlintide eller exendin-4 og en eller flere mucosal leveringsfremmende midler for øket nasal mucosal levering av amylinet, for behandling av forskjellige sykdommer og tilstander i mennesker, inkludert fedme og diabetes mellitus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53233703P | 2003-12-26 | 2003-12-26 | |
PCT/US2004/043312 WO2005065714A1 (en) | 2003-12-26 | 2004-12-17 | Intranasal administration of glucose-regulating peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063436L true NO20063436L (no) | 2006-08-25 |
Family
ID=34748791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063436A NO20063436L (no) | 2003-12-26 | 2006-07-25 | Intranasal administrasjon av glukose-regulerende peptider |
Country Status (16)
Country | Link |
---|---|
US (1) | US20050143303A1 (no) |
EP (1) | EP1696960B1 (no) |
JP (1) | JP2007518722A (no) |
KR (1) | KR20060134036A (no) |
CN (1) | CN1933855A (no) |
AT (1) | ATE480259T1 (no) |
AU (1) | AU2004312043B2 (no) |
CA (1) | CA2551530A1 (no) |
DE (1) | DE602004029086D1 (no) |
ES (1) | ES2350487T3 (no) |
IL (1) | IL176541A0 (no) |
MX (1) | MXPA06007317A (no) |
NO (1) | NO20063436L (no) |
NZ (1) | NZ548695A (no) |
WO (1) | WO2005065714A1 (no) |
ZA (1) | ZA200606153B (no) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070032410A1 (en) * | 2000-01-11 | 2007-02-08 | Atossa Healthcare, Inc. | Compositions and methods for the treatment of psychiatric disorders |
US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
EP1408896B1 (en) * | 2001-06-22 | 2016-01-20 | CPEX Pharmaceuticals, Inc. | Pharmaceutical composition |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
EP1478406B1 (en) * | 2002-02-27 | 2011-01-05 | PharmaIN Corporation | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
EP1631308B1 (en) * | 2003-05-30 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
US20060074025A1 (en) * | 2003-12-26 | 2006-04-06 | Nastech Pharmaceutical Company Inc. | Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
WO2005112977A2 (en) * | 2004-04-23 | 2005-12-01 | Pharmain, Ltd. | Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
US20090069226A1 (en) * | 2004-05-28 | 2009-03-12 | Amylin Pharmaceuticals, Inc. | Transmucosal delivery of peptides and proteins |
EP1773293B1 (en) | 2004-06-17 | 2015-04-15 | Endo Pharmaceuticals Solutions Inc. | Compositions and methods for treating central precocious puberty |
KR101123549B1 (ko) * | 2004-11-01 | 2012-04-18 | 아밀린 파마슈티칼스, 인크. | 비만 및 관련 장애의 치료 |
US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
JP4584331B2 (ja) * | 2005-03-11 | 2010-11-17 | インデバス ファーマシューティカルズ、インク. | オクトレオチドの放出制御製剤 |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
WO2007029238A2 (en) * | 2005-09-06 | 2007-03-15 | Oramed Pharmaceuticals, Inc. | Methods and compositions for oral administration of proteins |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
WO2007061434A2 (en) * | 2005-11-10 | 2007-05-31 | Nastech Pharmaceutical Company Inc. | A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome |
MX2008007075A (es) * | 2005-12-02 | 2008-11-12 | Mdrna Inc | Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa. |
BRPI0620571A2 (pt) * | 2005-12-08 | 2011-11-22 | Nastech Pharm Co | formulação farmacêutica aquosa, forma de dosagem de exendina, solução aquosa, uso de uma formulação farmacêutica, e uso de uma formulação farmacêutica aquosa |
ES2390286T3 (es) | 2005-12-16 | 2012-11-08 | Nektar Therapeutics | Conjugados poliméricos de GLP-1 |
AU2006330610B2 (en) | 2005-12-19 | 2012-08-16 | Pharmain Corporation | Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same |
US20090318502A1 (en) * | 2006-03-22 | 2009-12-24 | Intranasal Therapeutics, Inc. | Pharmaceutical Compositions Comprising a Hypoglycemic Agent and Methods of Using Same |
WO2007146448A1 (en) * | 2006-06-07 | 2007-12-21 | Nastech Pharmaceutical Company Inc. | Pharmaceutical formulations of glp-1 derivatives |
JP2010043001A (ja) * | 2006-11-09 | 2010-02-25 | Sanwa Kagaku Kenkyusho Co Ltd | Glp−1誘導体とその用途 |
CA2685397C (en) * | 2007-04-27 | 2016-07-26 | Endo Pharmaceuticals Solutions Inc. | Implant device release agents and methods of using same |
US7960336B2 (en) | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
RU2010113985A (ru) * | 2007-09-11 | 2011-10-20 | Мондобайотек Лабораториз Аг (Li) | Применение уродилатина в качестве терапевтического средства |
US20090176892A1 (en) * | 2008-01-09 | 2009-07-09 | Pharmain Corporation | Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same |
CA2719272C (en) | 2008-03-26 | 2020-08-18 | Oramed Ltd. | Methods and compositions for oral administration of proteins |
CN101548961B (zh) * | 2008-04-03 | 2011-05-04 | 单宝华 | 一种治疗糖尿病及肥胖症的口服胶囊制剂 |
AU2009245294B2 (en) | 2008-05-05 | 2014-02-20 | Oramed Ltd. | Methods and compositions for oral administration of exenatide |
US7960335B2 (en) * | 2008-06-25 | 2011-06-14 | Endo Pharmaceuticals Solutions Inc. | Octreotide implant having a release agent and uses thereof |
EP2303226B1 (en) | 2008-06-25 | 2016-03-23 | Endo Pharmaceuticals Solutions Inc. | Sustained delivery of exenatide and other polypeptides |
PL2393828T3 (pl) | 2009-02-03 | 2017-06-30 | Amunix Operating Inc. | Wydłużone rekombinowane polipeptydy i zawierające je kompozycje |
US20100203014A1 (en) * | 2009-02-04 | 2010-08-12 | Aegis Therapeutics Llc | Zwitterionic buffered acidic peptide and protein formulations |
CN101822822A (zh) * | 2009-03-04 | 2010-09-08 | 北京德众万全药物技术开发有限公司 | 一种普兰林肽的药物组合物及其制备方法 |
CN102481331B (zh) | 2009-06-08 | 2017-09-22 | 阿穆尼克斯运营公司 | 葡萄糖调节多肽及其制备和使用方法 |
CN102309453A (zh) * | 2011-09-27 | 2012-01-11 | 四川大学 | 醋酸艾塞那肽多囊脂质体及其制备方法 |
WO2013102899A1 (en) | 2012-01-03 | 2013-07-11 | Oramed Ltd. | Methods and compositions for treating diabetes |
DK2814504T3 (da) | 2012-02-01 | 2022-05-02 | Oramed Ltd | Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
SI2934567T1 (sl) | 2012-12-21 | 2018-10-30 | Sanofi | Derivati eksendina-4 kot dualni GLP1/GIP ali trigonalni agonisti GLP1/GIP/glukagon |
CN110151979A (zh) | 2013-01-03 | 2019-08-23 | 奥拉姆德有限公司 | 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物 |
BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
CN103405753B (zh) * | 2013-08-13 | 2016-05-11 | 上海仁会生物制药股份有限公司 | 稳定的促胰岛素分泌肽水针药物组合物 |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
CN103948544B (zh) * | 2014-04-08 | 2016-02-17 | 河南农业大学 | 重组Exendin-4鼻腔喷雾剂及其制备方法 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
EP3117831A1 (en) * | 2015-07-16 | 2017-01-18 | Nuritas Limited | Peptides for use in promoting transport of glucose into skeletal muscle |
MA46990B1 (fr) | 2017-08-24 | 2024-03-29 | Novo Nordisk As | Compositions glp-1 et ses utilisations |
CN108079280B (zh) * | 2017-12-30 | 2021-06-04 | 陕西慧康生物科技有限责任公司 | 治疗ⅱ型糖尿病的艾塞那肽滴鼻剂 |
CN109136176A (zh) * | 2018-07-03 | 2019-01-04 | 华东师范大学 | 一种小鼠冻存精子复苏液复合物及其配制方法和应用 |
EP4106724A1 (en) | 2020-02-18 | 2022-12-28 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
EP4404912A1 (en) * | 2021-09-22 | 2024-07-31 | Ferring B.V. | Adrenocorticotropic hormone peptide compositions and methods of use |
CN118001259B (zh) * | 2024-02-06 | 2024-09-20 | 上海万良诚科医药科技有限公司 | 曲普瑞林口颊膜及其制备方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US3972995A (en) * | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
JPS5562012A (en) * | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
GB2042888B (en) * | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
JPS57110254A (en) * | 1980-12-29 | 1982-07-09 | Teijin Ltd | Coating agent of injured membrane part of oral cavity |
JPS58500845A (ja) * | 1981-06-04 | 1983-05-26 | デラウェア・ケミカルス・コーポレーション | ポンプ |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
US4680323A (en) * | 1983-12-01 | 1987-07-14 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
US4573996A (en) * | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
US4740365A (en) * | 1984-04-09 | 1988-04-26 | Toyo Boseki Kabushiki Kaisha | Sustained-release preparation applicable to mucous membrane in oral cavity |
CA1256638A (en) * | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
JP2551756B2 (ja) * | 1985-05-07 | 1996-11-06 | 武田薬品工業株式会社 | ポリオキシカルボン酸エステルおよびその製造法 |
JPH0729915B2 (ja) * | 1986-02-01 | 1995-04-05 | 帝國製薬株式会社 | シ−ト状口腔内貼付剤 |
DE3750402T3 (de) | 1986-05-05 | 1997-04-10 | Gen Hospital Corp | Insulinotropes hormon. |
USRE33093E (en) * | 1986-06-16 | 1989-10-17 | Johnson & Johnson Consumer Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4855142A (en) * | 1987-02-27 | 1989-08-08 | Ciba-Geigy Corporation | Pharmaceutical plaster |
EP0308181A1 (en) * | 1987-09-14 | 1989-03-22 | Novo Nordisk A/S | Trans-mucosal delivery formulations and a method for preparation thereof |
US4948580A (en) * | 1988-12-08 | 1990-08-14 | E. R. Squibb & Sons, Inc. | Muco-bioadhesive composition |
NL9001681A (nl) * | 1990-07-24 | 1992-02-17 | Rijksuniversiteit | Transmucosale geneesmiddelpreparaten en transmucosale toediening. |
DK36492D0 (da) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Praeparat |
US6190894B1 (en) * | 1993-03-19 | 2001-02-20 | The Regents Of The University Of California | Method and compositions for disrupting the epithelial barrier function |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
JPH0859503A (ja) * | 1994-08-26 | 1996-03-05 | Teijin Ltd | ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤 |
US6004583A (en) * | 1995-03-22 | 1999-12-21 | Orex Pharmaceutical Development Corp. | Protein-containing polymer composition for oral administration |
JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
DE59712555D1 (de) * | 1996-06-05 | 2006-04-06 | Roche Diagnostics Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
US7312196B2 (en) * | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US5908825A (en) * | 1997-01-09 | 1999-06-01 | University Of Maryland At Baltimore | Dosage composition for nasal delivery and method of use of the same |
US6221378B1 (en) * | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
US20030087820A1 (en) * | 1999-01-14 | 2003-05-08 | Young Andrew A. | Novel exendin agonist formulations and methods of administration thereof |
US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
US6528486B1 (en) * | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
US20010012829A1 (en) * | 2000-01-11 | 2001-08-09 | Keith Anderson | Transepithelial delivery GLP-1 derivatives |
US6540983B1 (en) * | 2000-01-25 | 2003-04-01 | Aeropharm Technology Incorporated | Medical aerosol formulation |
US20050222036A1 (en) * | 2000-08-24 | 2005-10-06 | Thomas Jefferson University | Peptide compositions with effects on blood glucose |
US20030119734A1 (en) * | 2001-06-28 | 2003-06-26 | Flink James M. | Stable formulation of modified GLP-1 |
US6995180B2 (en) * | 2002-10-23 | 2006-02-07 | Bristol Myers Squibb Company | Glycinenitrile-based inhibitors of dipeptidyl peptidase IV and methods |
US20040258663A1 (en) * | 2003-05-08 | 2004-12-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of interferon alpha |
EP1631308B1 (en) * | 2003-05-30 | 2013-07-31 | Amylin Pharmaceuticals, LLC | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
US20060210614A1 (en) * | 2003-12-26 | 2006-09-21 | Nastech Pharmaceutical Company Inc. | Method of treatment of a metabolic disease using intranasal administration of exendin peptide |
-
2004
- 2004-11-18 US US10/991,597 patent/US20050143303A1/en not_active Abandoned
- 2004-12-17 JP JP2006547366A patent/JP2007518722A/ja active Pending
- 2004-12-17 AT AT04815393T patent/ATE480259T1/de not_active IP Right Cessation
- 2004-12-17 CA CA002551530A patent/CA2551530A1/en not_active Abandoned
- 2004-12-17 DE DE602004029086T patent/DE602004029086D1/de active Active
- 2004-12-17 WO PCT/US2004/043312 patent/WO2005065714A1/en active Application Filing
- 2004-12-17 AU AU2004312043A patent/AU2004312043B2/en not_active Ceased
- 2004-12-17 ES ES04815393T patent/ES2350487T3/es active Active
- 2004-12-17 NZ NZ548695A patent/NZ548695A/en unknown
- 2004-12-17 EP EP04815393A patent/EP1696960B1/en not_active Not-in-force
- 2004-12-17 KR KR1020067015029A patent/KR20060134036A/ko not_active Application Discontinuation
- 2004-12-17 MX MXPA06007317A patent/MXPA06007317A/es active IP Right Grant
- 2004-12-17 CN CNA2004800421626A patent/CN1933855A/zh active Pending
-
2006
- 2006-06-25 IL IL176541A patent/IL176541A0/en unknown
- 2006-07-25 ZA ZA200606153A patent/ZA200606153B/xx unknown
- 2006-07-25 NO NO20063436A patent/NO20063436L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN1933855A (zh) | 2007-03-21 |
ATE480259T1 (de) | 2010-09-15 |
AU2004312043B2 (en) | 2008-07-31 |
MXPA06007317A (es) | 2007-01-26 |
NZ548695A (en) | 2008-04-30 |
AU2004312043A1 (en) | 2005-07-21 |
EP1696960B1 (en) | 2010-09-08 |
KR20060134036A (ko) | 2006-12-27 |
US20050143303A1 (en) | 2005-06-30 |
ES2350487T3 (es) | 2011-01-24 |
JP2007518722A (ja) | 2007-07-12 |
CA2551530A1 (en) | 2005-07-21 |
WO2005065714A1 (en) | 2005-07-21 |
DE602004029086D1 (de) | 2010-10-21 |
EP1696960A1 (en) | 2006-09-06 |
IL176541A0 (en) | 2006-10-05 |
ZA200606153B (en) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063436L (no) | Intranasal administrasjon av glukose-regulerende peptider | |
AR022368A1 (es) | Procedimiento para administrar peptidos insulinotropicos | |
ATE251642T1 (de) | Biologisch aktive fragmente des glucagon ähnlichen, insulinotropen peptides | |
Lorenz et al. | Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity | |
WO2006121860A3 (en) | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use | |
PL2301962T3 (pl) | Wynalazek dotyczący glp-1 i eksendyny | |
WO2003011892A3 (en) | Glp-1 exendin-4 peptide analogs and uses thereof | |
WO2003033671A3 (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
NO20071018L (no) | Kombinasjonsbehandling ved a anvende fusjonsproteiner omfattende GLP-1 | |
NO20082958L (no) | Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav for behandling av diabetes og beslektede tilstander | |
NO20070614L (no) | Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav ved behandling av diabetes og beslektede tilstander. | |
Chae et al. | Preparation, characterization, and application of biotinylated and biotin− PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery | |
WO2008015099A3 (en) | Pegylated, extended insulins | |
EA200870575A1 (ru) | Композиции и способы лечения застойной сердечной недостаточности | |
NZ621196A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
JP2004509079A5 (no) | ||
UA97953C2 (uk) | Стабілізовані поліпептиди інсуліноподібного фактора росту | |
WO2008022015A3 (en) | Retro-inverso incretin analogues, and methods of use thereof | |
WO1999043705A8 (en) | N-terminally truncated glp-1 derivatives | |
WO2004094461A3 (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
WO2008033395A3 (en) | Melanocortin and transferrin fusion proteins | |
Kim et al. | Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice | |
MX2022009149A (es) | Compuestos coagonistas de gip/glp1. | |
IL146868A0 (en) | A pharmaceutical composition containing an igf-i/igfbp-3 complex | |
Youn et al. | Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |